Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round

　　Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.

　　Founded in 2010, Jiangsu Vcare specializes in end-to-end R&D, services, and innovation across the chemical drug industry chain. Headquartered in Nanjing Biotech and Pharmaceutical Valley, the company employs 280 staff, with over 50% of its R&D team holding master’s or doctoral degrees. It operates a 21,000 sqm high-end drug R&D center equipped with fully functional synthesis, analysis, formulation, cell, and enzyme activity testing laboratories. Its experienced teams in medicinal chemistry, CMC, and clinical development operate under internationally advanced management models, providing comprehensive R&D capabilities spanning "Chemistry + Pharmacy + Medicine".

　　Focusing on unmet clinical needs in cardiovascular, oncology, and endocrine diseases, Jiangsu Vcare has developed multiple competitive innovative products through independent R&D and collaborative innovation. Its flagship drug Vicagrel—which has completed Phase II trials—was recognized as "one of the most commercially promising projects in its field." The second-generation NTRK inhibitor has entered Phase I, while a highly selective JAK1 inhibitor is nearing IND submission. The pipeline includes multiple first-in-class (FIC) and best-in-class (BIC) preclinical candidates.

　　In recent years, Jiangsu Vcare has steadily advanced its innovative drug programs while achieving rapid growth in contract services. With investor support, the company aims to accelerate clinical research and deliver more high-quality therapeutics to global patients.

　　Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We sincerely appreciate our investors’ recognition of Jiangsu Vcare and their trust in our team. We are in an exhilarating era of innovation, where developing novel drugs to address clinical needs remains our unwavering mission. Simultaneously, in this service-driven economy, we are committed to providing one-stop, full-process drug R&D services that create value for clients. Moving forward, we will continue to prioritize independent innovation and open collaboration to unlock limitless potential."